GLP-1 Drugs and Long-Term Safety: Side Effects, Muscle Loss, Tapering and Preventive Use

In recent years, GLP-1 receptor agonist medications such as Semaglutide and Tirzepatide have revolutionised the treatment of obesity and type 2 diabetes.

Beyond improving glycemic control, these drugs induce significant weight loss by reducing appetite, slowing gastric emptying, and improving insulin sensitivity.

However, while their effectiveness is well documented, the implications of long-term use deserve deeper consideration.

In this article, we explore four aspects that are often less discussed:

• side effects

• discontinuation and tapering

• muscle mass loss

• preventive use

GLP-1 Agonists: Side Effects Beyond Nausea

The most common side effects of GLP-1 agonists are gastrointestinal and include:

• nausea

• vomiting

• diarrhea

• constipation

• early satiety

These symptoms often decrease over time and are frequently dose-dependent.

However, other potential consequences are emerging that deserve attention, including:

• significantly slowed gastric emptying

• a possible increased risk of gallstones (cholelithiasis)

• reduced protein intake in patients experiencing strong appetite suppression

For many patients, the primary concern is not initial tolerability but rather the metabolic adaptation that may occur over the long term.

The Challenge of Discontinuation: What Occurs When Treatment Ceases?

One of the less discussed aspects concerns a form of functional therapeutic dependence.

Several studies show that after discontinuation of Semaglutide, many patients regain a significant portion of the weight they initially lost.

This happens because the drug:

• reduces appetite at the central nervous system level

• modifies satiety signalling

• influences dopamine-related reward circuits linked to food

When the medication is stopped, these mechanisms gradually return to their previous state.

For this reason, some clinicians are beginning to discuss tapering strategies, meaning a gradual dose reduction combined with:

• nutritional education

• increased physical activity

• targeted nutritional support

Sarcopenia: Weight Loss Isn’t Always Fat Loss

A crucial issue concerns the quality of weight loss.

Weight reduction with GLP-1 agonists may include a significant proportion of lean body mass, particularly when protein intake and resistance training are not optimised.

Loss of muscle mass can have important metabolic consequences:

• reduction in basal metabolic rate

• increased risk of sarcopenia over time

• greater likelihood of weight regain

For this reason, many specialists recommend combining treatment with:

• adequate protein intake

• resistance training

• monitoring of body composition

Preventive Use: A Continuing Challenge

With the growing popularity of these medications, an important question is emerging:

Does it make sense to use GLP-1 agonists preventively in individuals with moderate overweight?

From a metabolic perspective, the idea is intriguing: intervening before the development of diabetes or severe obesity.

However, several questions remain:

• long-term safety over decades

• economic sustainability

• how discontinuation should be managed

• the impact on muscle mass and eating behaviour

It is therefore likely that, in the coming years, the focus will shift toward integrated strategies in which medication, nutrition, and lifestyle interventions work together.

New Approaches: Lowering Doses and "Micro-Dosing"

Another strategy that is beginning to emerge in clinical practice is the possibility of progressively reducing the dose to maintain results over time.

Instead of stopping treatment completely, some physicians are experimenting with maintenance dosing or micro-dosing approaches using GLP-1 agonists such as Semaglutide or Tirzepatide.

The idea is that a lower dose than the one used for active weight loss may be sufficient to:

• maintain appetite control

• stabilise body weight

• reduce side effects

• limit weight regain after the initial weight-loss phase

However, it is important to emphasise that these approaches are still under investigation, and no universally defined protocols currently exist.

In the coming years, it will likely become increasingly important to determine the minimum effective dose capable of maintaining metabolic benefits over the long term, while integrating pharmacological therapy with nutrition and physical activity.